RCUS - Arcus Biosciences Inc

RCUS - Arcus Biosciences Inc

https://www.arcusbio.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Uranium Energy ( AMEX:UEC ) , Arcus Biosciences ( NYSE:RCUS )

Benzinga • 1 month ago • score: 0.12

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, "I like nuclear." Supporting his view, HC Wainwright & Co. analyst Heiko F. Ihle, on Aug. 6, maintained Uranium Energy with a Buy and raised the price target from $12.25 to $12.75.

Arcus Biosciences, Inc. ( RCUS ) Reports Break-Even Earnings for Q2

Zacks Commentary • 1 month, 1 week ago • score: 0.10

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. ( RCUS ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.04

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. ( RCUS ) Reports Q4 Loss, Tops Revenue Estimates

Zacks Commentary • 6 months, 2 weeks ago • score: 0.07

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 11.97% and 9.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.

52W High

$18.98

52W Low

$6.50

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.83

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

3.96

EV/Revenue (<3 favorable)

1.89

P/S (TTM) (<3 favorable)

4.95

P/B (<3 favorable)

2.36

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

34.76%

Institutions (25–75% balanced)

67.52%

Shares Outstanding

106,431,000

Float

59,889,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

262,000,000

Gross Profit (TTM)

-223,000,000

EPS (TTM)

-3.14

Profit Margin (>10% good)

-1.14%

Operating Margin (TTM) (higher better)

-0.05%

ROE (TTM) (>15% strong)

-0.50%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

3.10

Momentum

Bearish momentum

Value

0.5928

Previous

0.6162

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025